Prodromal language impairment in genetic frontotemporal dementia within the GENFI cohort.


Journal

Journal of the neurological sciences
ISSN: 1878-5883
Titre abrégé: J Neurol Sci
Pays: Netherlands
ID NLM: 0375403

Informations de publication

Date de publication:
15 08 2023
Historique:
received: 30 10 2022
revised: 01 06 2023
accepted: 08 06 2023
medline: 4 8 2023
pubmed: 23 6 2023
entrez: 22 6 2023
Statut: ppublish

Résumé

To identify whether language impairment exists presymptomatically in genetic frontotemporal dementia (FTD), and if so, the key differences between the main genetic mutation groups. 682 participants from the international multicentre Genetic FTD Initiative (GENFI) study were recruited: 290 asymptomatic and 82 prodromal mutation carriers (with C9orf72, GRN, and MAPT mutations) as well as 310 mutation-negative controls. Language was assessed using items from the Progressive Aphasia Severity Scale, as well as the Boston Naming Test (BNT), modified Camel and Cactus Test (mCCT) and a category fluency task. Participants also underwent a 3 T volumetric T1-weighted MRI from which regional brain volumes within the language network were derived and compared between the groups. 3% of asymptomatic (4% C9orf72, 4% GRN, 2% MAPT) and 48% of prodromal (46% C9orf72, 42% GRN, 64% MAPT) mutation carriers had impairment in at least one language symptom compared with 13% of controls. In prodromal mutation carriers significantly impaired word retrieval was seen in all three genetic groups whilst significantly impaired grammar/syntax and decreased fluency was seen only in C9orf72 and GRN mutation carriers, and impaired articulation only in the C9orf72 group. Prodromal MAPT mutation carriers had significant impairment on the category fluency task and the BNT whilst prodromal C9orf72 mutation carriers were impaired on the category fluency task only. Atrophy in the dominant perisylvian language regions differed between groups, with earlier, more widespread volume loss in C9orf72, and later focal atrophy in the temporal lobe in MAPT mutation carriers. Language deficits exist in the prodromal but not asymptomatic stages of genetic FTD across all three genetic groups. Improved understanding of the language phenotype prior to phenoconversion to fully symptomatic FTD will help develop outcome measures for future presymptomatic trials.

Identifiants

pubmed: 37348248
pii: S0022-510X(23)00172-7
doi: 10.1016/j.jns.2023.120711
pii:
doi:

Substances chimiques

Progranulins 0
C9orf72 Protein 0
tau Proteins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

120711

Investigateurs

Annabel Nelson (A)
David L Thomas (DL)
Emily Todd (E)
Hanya Benotmane (H)
Jennifer Nicholas (J)
Rachelle Shafei (R)
Carolyn Timberlake (C)
Thomas Cope (T)
Timothy Rittman (T)
Alberto Benussi (A)
Enrico Premi (E)
Roberto Gasparotti (R)
Silvana Archetti (S)
Stefano Gazzina (S)
Valentina Cantoni (V)
Andrea Arighi (A)
Chiara Fenoglio (C)
Elio Scarpini (E)
Giorgio Fumagalli (G)
Vittoria Borracci (V)
Giacomina Rossi (G)
Giorgio Giaccone (G)
Giuseppe Di Fede (G)
Paola Caroppo (P)
Sara Prioni (S)
Veronica Redaelli (V)
David Tang-Wai (D)
Ekaterina Rogaeva (E)
Miguel Castelo-Branco (M)
Morris Freedman (M)
Ron Keren (R)
Sandra Black (S)
Sara Mitchell (S)
Christen Shoesmith (C)
Robart Bartha (R)
Rosa Rademakers (R)
Jackie Poos (J)
Janne M Papma (JM)
Lucia Giannini (L)
Rick van Minkelen (R)
Yolande Pijnenburg (Y)
Benedetta Nacmias (B)
Camilla Ferrari (C)
Cristina Polito (C)
Gemma Lombardi (G)
Valentina Bessi (V)
Michele Veldsman (M)
Christin Andersson (C)
Hakan Thonberg (H)
Linn Öijerstedt (L)
Vesna Jelic (V)
Paul Thompson (P)
Tobias Langheinrich (T)
Albert Lladó (A)
Anna Antonell (A)
Jaume Olives (J)
Mircea Balasa (M)
Nuria Bargalló (N)
Sergi Borrego-Ecija (S)
Ana Verdelho (A)
Carolina Maruta (C)
Catarina B Ferreira (CB)
Gabriel Miltenberger (G)
Frederico Simões do Couto (FS)
Alazne Gabilondo (A)
Ana Gorostidi (A)
Jorge Villanua (J)
Marta Cañada (M)
Mikel Tainta (M)
Miren Zulaica (M)
Myriam Barandiaran (M)
Patricia Alves (P)
Benjamin Bender (B)
Carlo Wilke (C)
Lisa Graf (L)
Annick Vogels (A)
Mathieu Vandenbulcke (M)
Philip Van Damme (P)
Rose Bruffaerts (R)
Koen Poesen (K)
Pedro Rosa-Neto (P)
Serge Gauthier (S)
Agnès Camuzat (A)
Alexis Brice (A)
Anne Bertrand (A)
Aurélie Funkiewiez (A)
Daisy Rinaldi (D)
Dario Saracino (D)
Olivier Colliot (O)
Sabrina Sayah (S)
Catharina Prix (C)
Elisabeth Wlasich (E)
Olivia Wagemann (O)
Sandra Loosli (S)
Sonja Schönecker (S)
Tobias Hoegen (T)
Jolina Lombardi (J)
Sarah Anderl-Straub (S)
Adeline Rollin (A)
Gregory Kuchcinski (G)
Maxime Bertoux (M)
Thibaud Lebouvier (T)
Vincent Deramecourt (V)
Beatriz Santiago (B)
Diana Duro (D)
Maria João Leitão (MJ)
Maria Rosario Almeida (MR)
Miguel Tábuas-Pereira (M)
Sónia Afonso (S)

Informations de copyright

Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no competing interests.

Auteurs

Kiran Samra (K)

Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK.

Amy M MacDougall (AM)

Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London, UK.

Arabella Bouzigues (A)

Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK.

Martina Bocchetta (M)

Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK.

David M Cash (DM)

Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK.

Caroline V Greaves (CV)

Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK.

Rhian S Convery (RS)

Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK.

John C van Swieten (JC)

Department of Neurology, Erasmus Medical Centre, Rotterdam, Netherlands.

Lize Jiskoot (L)

Department of Neurology, Erasmus Medical Centre, Rotterdam, Netherlands.

Harro Seelaar (H)

Department of Neurology, Erasmus Medical Centre, Rotterdam, Netherlands.

Fermin Moreno (F)

Cognitive Disorders Unit, Department of Neurology, Donostia Universitary Hospital, San Sebastian, Spain; Neuroscience Area, Biodonostia Health Research Institute, San Sebastian, Gipuzkoa, Spain.

Raquel Sanchez-Valle (R)

Alzheimer's disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clínic, Institut d'Investigacións Biomèdiques August Pi I Sunyer, University of Barcelona, Barcelona, Spain.

Robert Laforce (R)

Clinique Interdisciplinaire de Mémoire, Département des Sciences Neurologiques, CHU de Québec, and Faculté de Médecine, Université Laval, QC, Canada.

Caroline Graff (C)

Center for Alzheimer Research, Division of Neurogeriatrics, Department of Neurobiology, Care Sciences and Society, Bioclinicum, Karolinska Institutet, Solna, Sweden; Unit for Hereditary Dementias, Theme Aging, Karolinska University Hospital, Solna, Sweden.

Mario Masellis (M)

Sunnybrook Health Sciences Centre, Sunnybrook Research Institute, University of Toronto, Toronto, Canada.

Maria Carmela Tartaglia (MC)

Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, ON, Canada.

James B Rowe (JB)

Department of Clinical Neurosciences, University of Cambridge, UK.

Barbara Borroni (B)

Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.

Elizabeth Finger (E)

Department of Clinical Neurological Sciences, University of Western Ontario, London, ON, Canada.

Matthis Synofzik (M)

Department of Neurodegenerative Diseases, Hertie-Institute for Clinical Brain Research and Center of Neurology, University of Tübingen, Tübingen, Germany; Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany.

Daniela Galimberti (D)

Fondazione Ca' Granda, IRCCS Ospedale Policlinico, Milan, Italy; University of Milan, Centro Dino Ferrari, Milan, Italy.

Rik Vandenberghe (R)

Laboratory for Cognitive Neurology, Department of Neurosciences, KU Leuven, Leuven, Belgium; Neurology Service, University Hospitals Leuven, Leuven, Belgium; Leuven Brain Institute, KU Leuven, Leuven, Belgium.

Alexandre de Mendonça (A)

Laboratory of Neurosciences, Institute of Molecular Medicine, Faculty of Medicine, University of Lisbon, Lisbon, Portugal.

Chris R Butler (CR)

Nuffield Department of Clinical Neurosciences, Medical Sciences Division, University of Oxford, Oxford, UK; Department of Brain Sciences, Imperial College London, UK.

Alex Gerhard (A)

Division of Neuroscience and Experimental Psychology, Wolfson Molecular Imaging Centre, University of Manchester, Manchester, UK; Departments of Geriatric Medicine and Nuclear Medicine, University of Duisburg-Essen, Germany.

Simon Ducharme (S)

Department of Psychiatry, McGill University Health Centre, McGill University, Montreal, Québec, Canada; McConnell Brain Imaging Centre, Montreal Neurological Institute, McGill University, Montreal, Québec, Canada.

Isabelle Le Ber (I)

Sorbonne Université, Paris Brain Institute - Institut du Cerveau - ICM, Inserm U1127, CNRS UMR 7225, AP-HP - Hôpital Pitié-Salpêtrière, Paris, France; Centre de Référence des Démences rares ou Précoces, IM2A, Département de Neurologie, AP-HP - Hôpital Pitié-Salpêtrière, Paris, France; Département de Neurologie, AP-HP - Hôpital Pitié-Salpêtrière, Paris, France; Reference Network for Rare Neurological Diseases (ERN-RND).

Pietro Tiraboschi (P)

Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Italy.

Isabel Santana (I)

University Hospital of Coimbra (HUC), Neurology Service, Faculty of Medicine, University of Coimbra, Coimbra, Portugal; Center for Neuroscience and Cell Biology, Faculty of Medicine, University of Coimbra, Coimbra, Portugal.

Florence Pasquier (F)

Univ Lille, France; Inserm 1172, Lille, France; CHU, CNR-MAJ, Labex Distalz, LiCEND Lille, France.

Johannes Levin (J)

Department of Neurology, Ludwig-Maximilians Universität München, Munich, Germany; German Center for Neurodegenerative Diseases (DZNE), Munich, Germany; Munich Cluster of Systems Neurology (SyNergy), Munich, Germany.

Markus Otto (M)

Department of Neurology, University of Ulm, Germany.

Sandro Sorbi (S)

Department of Neurofarba, University of Florence, Italy; IRCCS Fondazione Don Carlo Gnocchi, Florence, Italy.

Jonathan D Rohrer (JD)

Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK.

Lucy L Russell (LL)

Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK. Electronic address: l.russell@ucl.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH